Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 14, 2019
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 02, 2018
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
To Assess the Patients' Ability to Self-Administer Fasinumab
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 09, 2018
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 09, 2017
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasinumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 18, 2017
Lead Product(s) : Fasinumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 19, 2017
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 17, 2016
Lead Product(s) : Fasinumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasinumab
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 02, 2015
Lead Product(s) : Fasinumab
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasinumab
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 06, 2015
Lead Product(s) : Fasinumab
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable